Anosmia Clinical Trials 2022

Browse 4 Anosmia Medical Studies Across 4 Cities

4 Anosmia Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Stellate Ganglion Blockfor Olfactory Disorders

Saint Louis, MO
18+
All Sexes
Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs. Olfactory dysfunction is also an independent predictor of anxiety, depression, and even mortality. While the pandemic has increased the interest by the scientific community in combating the burgeoning health crisis, few effective treatments currently exist for olfactory dysfunction. Furthermore, patients impacted by "long COVID," or chronic symptoms after an acute COVID-19 infection, experience impairments other than olfactory and gustatory dysfunction, such as chronic dyspnea, impaired memory and concentration, and severe fatigue. These symptoms have been hypothesized to be a result of sympathetic positive feedback loops and dysautonomia. Stellate ganglion blocks have been proposed to treat this hyper-sympathetic activation by blocking the sympathetic neuronal firing and resetting the balance of the autonomic nervous system. Studies prior to the COVID-19 pandemic have supported a beneficial effect of stellate ganglion blocks on olfactory dysfunction, and recent news reports and a published case series have described a dramatic benefit in both olfactory function and other long COVID symptoms in patients receiving stellate ganglion blocks. Therefore, we propose a single cohort prospective study to generate pilot data on the efficacy and safety of sequential stellate ganglion blocks for the treatment of COVID-19-induced olfactory dysfunction and other long COVID symptoms.
Phase 1 & 2
Recruiting
Phase-Based Progress Estimates
3
Effectiveness
3
Safety

Aerosolized All Trans Retinoic Acidfor Anosmia

Tampa, FL
18+
All Sexes
Investigating the potential role of Aerosolized retinoic acid, a potent Vitamin A metabolite for treating COVID-19 Anosmia and retinoic acid insufficiency .A novel approach for regaining Sense of Smell. Mahmoud ELkazzaz(1),Tamer Haydara(2), Abedelaziz Elsayed(3) ,Yousry Abo-amer(4), Hesham Attia(5), Quan Liu(6) and Amr Ahmed(7) Department of chemistry and biochemistry, Faculty of Science, Damietta University, Egypt. Department of Internal Medicine, Faculty of Medicine, Kafrelsheikh University, Egypt Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tanta University, Egypt. Hepatology,Gastroenterology and Infectious Diseases Department, Mahala Hepatology Teaching Hospital, Egypt Department of Immunology and Parasitology, Faculty of Science, Cairo University, Egypt. School of Life Sciences and Engineering, Foshan University, Laboratory of Emerging Infectious Disease, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, China. Director of tuberculosis program Ghubera, public health department ,First health cluster ,Ministry of health ,Saudia Arabia. Very important Note: This clinical study is the first clinical study in literature (First posted August 12, 2021) which demonstrated depending on molecular findings that Vitamin A /Retinoic Acid will treat smell loss resulted by COVID-19 Recent rapidly accumulating evidences and reports indicate that partial loss of the sense of smell or even total anosmia are early markers of SARS-CoV-2 infection and frequently reported symptoms associated with the COVID-19 pandemic (Lechien J. R et al., 2020) However, the cellular mechanisms of this phenomenon are unknown. The rates of insomnia and depression were 26.45% and 9.92% in the COVID-19 patients after recovery. Therefore, finding an effective treatment for COVID-19 Anosmia is a critical point. Although, ACE2 has been identified as the principal host cell receptor of 2019-nCoV, and it is thought to play a critical role in the virus's entrance into the cell and subsequent infection, many cells can be infected by COVID-19 while also expressing little or no ACE2. Even though the COVID-19 entry receptor, angiotensin-converting enzyme 2 (ACE2), is not expressed in the receptor of olfactory neurons, or its synthesis is limited to to a minor fraction of these neurons.of these neurons, COVID-19 infection causes a loss of smell (anosmia) (Katarzyna Bilinska et al.,2021). Our recent findings showed that COVID-19 binds directly to STRA6 receptors of retinol leading to retinol depletion and retinoic acid insufficiency (M Elkazzaz et al,. 2021) . Retinoic acid insufficiency in the olfactory epithelium, both in mouse and chick models, causes progenitor cell maintenance failure and, consequently, olfactory neurons differentiation is not maintained . An explant system, showed that renewal of olfactory neurons is inhibited if retinoic acid synthesis was failed in the olfactory epithelium (Paschaki M et al., 2013) . It's worth noting that vitamin A shortage also causes olfactory and taste problems, In a study by Garrett-Laster et al., (1984), the patients had vitamin A deficiency because of malnutrition and alcoholic liver cirrhosis; they lost their sense of smell after that disorder. LaMantia and Rawson et al.,( 2007) reported that administration of retinoid acid after the damage of olfactory system motivates an immune response and produces a more quick recovery of olfactoryguided behavior. It was showed that Isotretinoin improved the significantly performance of patients in the olfactory test(Demet Kartal et al.,2017) Moreover, there is increasing evidence that retinoic acid (atRA) influences gene expression of components of renin-angiotensin system (RAS), which plays a pivotal role in the pathophysiology of essential hypertension. Retinoic acid induced ACE2 expression in different animal models. Moreover, a study suggests that topical retinoids may have applicability in promoting sinus regeneration and wound healing. In a study comparing treated and untreated nasal mucosa ,untreated regenerated mucosa showed expected changes of submucosal gland loss, basal lamina and lamina propria fibrosis and loss of cilia. Reinoic acid treatment appeared to result in better mucosal regeneration marked by less cellular atypia and fibrosis(Mendy S. Maccabee et al,. 2003).. Aerosolized retinoic acid will have an effective role in treating post COVID-19 anosmia (loss of smell) via upregulating ACE2, STRA 6 and regenerating of olfactory receptors and olfactory sensory cells and neurons.
Phase 4
Waitlist Available
4 Anosmia Clinical Trials Near Me
Saint Louis, MO
Trois-Rivières, Canada
Tampa, FL
Pittsburgh, PA
An interactive map to display trial locations for Washington University School of Medicine/Barnes Jewish Hospital, Université du Québec à Trois-Rivières, Michelle Orzechowski, UPMC Children's Hospital of Pittsburgh.
Most Popular References for Anosmia Clinical Trials
Frequency
Citation
Top Hospitals for Anosmia Clinical Trials
Location
Active Anosmia Clinical Trials
All Time Trials for Anosmia
First Recorded Anosmia Trial
Trials
Washington University School of Medicine/Barnes Jewish Hospital, Saint Louis, Missouri
1
1
2022
Université du Québec à Trois-Rivières, Trois-Rivières, Quebec
1
1
2022
Michelle Orzechowski, Tampa, Florida
1
1
2022
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
1
1
2022
Top Treatments for Anosmia Clinical Trials
Treatment Name
Active Anosmia Clinical Trials
All Time Trials for Anosmia
First Recorded Anosmia Trial
Trials
Smell training
1
1
2022
Aerosolized All trans retinoic acid
1
1
2021
Smell Retraining
1
1
2021
Top Cities for Anosmia Clinical Trials
City
Active Anosmia Clinical Trials
Top Active Site for Anosmia Clinical Trials
Trial List
Saint Louis, Missouri
1
Washington University School of Medicine/Barnes Jewish Hospital
Trois-Rivières, Quebec
1
Université du Québec à Trois-Rivières
Tampa, Florida
1
Michelle Orzechowski
Pittsburgh, Pennsylvania
1
UPMC Children's Hospital of Pittsburgh
Which phases are most popular for anosmia clinical trials?
Phase
Active Anosmia Clinical Trials
Number of Unique Treatments
Number of Active Locations
Trial List
How many anosmia clinical trials are open to youth and / or seniors?
Most Recent Anosmia Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
9/30/2021
Phase 1 & 2
Pediatric Anosmia Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
9/30/2021
Phase 1 & 2
Senior Friendly Anosmia Clinical Trials
Clinical Trial
Began Recruiting Date
Phase

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: August 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.